Andrew Combs

Executive

Insider activity · 24 months2 buys0 salesCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 1 buy · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 0 salesMar 25 · 1 buy · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Company

▲ Purchases (6 ops.)

€246k

▼ Sales (0 ops.)

—

Latest filing published 27 Mar 2025 for Prelude Therapeutics Inc, €64k.

Filing timeline

BuySale

Andrew Combs

Insider track record

Disclosed buys

Disclosed sells

T+90 hit rate

33%

T+90 mean return

-21.5%

Across 3 buy signals with a settled T+90 return. Return basis: close on the day after publication.

Signal history

Andrew Combs: trading record in brief

This profile gathers the share dealings of Andrew Combs in Prelude Therapeutics Inc, where the filings describe the role as chief executive. We count 7 filings; the first trade dates from 29 September 2020 and the latest from 25 March 2025.

On the market, this insider has only ever bought: 6 purchases, €246k in total. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Besides market trades, the filings include 1 option exercise. 2025 to date brings 1 purchase and no sales.

In size, the median ticket on the buying side is €42k. On 4 out of 6 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time.

The latest filing, published on 27 March 2025, reports an open-market purchase of €64k in Prelude Therapeutics Inc. The median gap between a trade and its publication by SEC (Form 4) is 2 days. US insiders must file a Form 4 within two business days of a trade. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.